Addressing Key Translational Challenges of Base Editing Technology

Time: 1:45 pm
day: Day 2 Track B PM


  • For somatic base editing programs, how can a drug sponsor prove no germline edits have occurred?
  • Detection of on- and off-target genome editing events in the clinical setting
  • Outlining the unique regulatory considerations for clearing an IND with a base editing program